PUVA therapy for psoriasis: choosing a suitable régime by Samuel, M et al.
The Ulster Medical Journal, Volume 54, No. 2, pp. 196- 199, October 1985.
PUVA therapy for psoriasis: choosing a
suitable regime
M Samuel, R W Henry, G E Allen, A M T Kelly t
Accepted 6th June 1985.
SUMMARY
Three age- andsex-matchedgroups of30patients with chronicplaquepsoriasis
were treated by photochemotherapy (PUVA). Groups I and 1I received routine
maintenance PUVA therapy at different intervals and Group III had no mainten-
ance treatment. The remission time after the clearance treatment with PUVA is
compared with the total cumulative dose of long wave ultraviolet light (UVA).
A lower mean dose of UVA (51.0 ± 1.7 joules/cm2) in Group III (no
maintenance PUVA) achieved a comparable remission period to that after larger
cumulative doses following routine maintenance therapy (87.8 ± 4.9 and
77.0 ± 4.1joules/cm2 in Groups I and 11).
INTRODUCTION
Photochemotherapy using long wave high intensity ultraviolet rays and oral
psoralen (PUVA) is an effective although palliative treatment in chronic psoriasis I
with therapeutic efficacy comparable to dithranol application.2 Patient accept-
ance is high owing to minimal use of ointments, but potential long-term hazards
have not been clearly delineated. It is widely recognised that the possibility of
premature ageing, skin cancers, cataract formation, pigmentary changes and
alteration in the immune system are potential risks associated with PUVA
therapy.3 It is often necessary to use therapy continuously with consequent high
total cumulative doses of long wave ultraviolet rays (UVA). The problem of
finding safe and effective treatment for chronic plaque psoriasis remains, and
dermatologists are constantly striving to find an effective but safe protocol for
administering PUVA therapy. There is no general agreement as to whether a
maintenance regimen should be used or, if a maintenance regimen is used, what
form is effective with minimum exposure to UVA. Since PUVA therapy became
available in our skin unit we have been revising our treatment protocol in the light
of available data on PUVA therapy. There are only a few published reports
concerning the remission period following PUVA therapy and its relationship to
total UVA exposure. By constantly revising the treatment protocol, it became
possible to compare various regimes of PUVA therapy administered to our
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patients with psoriasis. The object of this retrospective study is to compare
groups ofpatients who had maintenance PUVA with a group who had received no
maintenance therapy with PUVA and to relate the total UVA exposure to the
length of remission period.
PATIENTS
Only patients with chronic stable plaque psoriasis were selected for the study. All
patients were assessed according to already published criteria2 prior to starting
PUVA therapy. Full clinical examination and laboratory tests (haemoglobin, total
white cell count, platelet count, serum bilirubin, alkaline phosphatase, aspartate
and alanine transaminase, gamma gluteryl transpeptidase and blood urea) were
carried out to exclude co-existing medical problems. The laboratory tests were
repeated once during the treatment and at the completion of PUVA therapy in
each case. A detailed ophthalmological examination was performed before
starting PUVA therapy and after the therapy in all cases. Only those with type 11
skin were included in the study. All had extensive involvement of their skin with
psoriasis, more than 10% oftheir body surface. Age ranged from 18 to 70 years,
mean 37 years. Three groups of 30 patients matched for age and sex were
analysed, depending upon the maintenance regimen of PUVA therapy used.
PUVA THERAPY
All patients were treated with PUVA three times weekly until their psoriasis
resolved completely, and thereafter according to the maintenance regimen
described below. The drug 8-methoxypsoralen was used in a dosage of 0.6
mg/kg body weight, given two hours before the UVA exposure. The initial dose of
UVA was 1.5 joules/cm2, increasing by 0.5 to 1.00 joules/cm2 every 3-4
treatments according to individual needs, using a Waldman 'PUVA 4000' unit.
Clinical clearance was considered to have occurred when the psoriatic lesions had
flattened completely, both visually and on palpation. The time taken to clear the
psoriasis ranged from 4 to 10 weeks.
Group L. After clearance of psoriasis this group was given weekly maintenance
treatment with progressive lengthening of the interval between treatments
finishing with one treatment every 3-4 weeks. This period of maintenance
PUVA was approximately 4 months. At this stage PUVA therapy was stopped.
Group 11. After the clearing regimen, patients were treated once every 3 weeks
with maintenance PUVA. Duration of maintenance varied from 6 to 7 months.
Group IIL. After the clearing regimen, no maintenance treatment was given.
All patients were reviewed at 2 months after stopping PUVA therapy and there-
after if they relapsed. A relapse was considered -to-have occurred with the
development of new lesions of psoriasis involving about 5% ofthe body surface.
Remission time was calculated from the time clearance therapy was stopped until
relapse. Patients were observed for a period ranging from 2 months to 24
months. Statistical analysis was performed using the paired t test.4
RESULTS
The number of treatments to clear psoriasis in each group was the same (Table).
The three groups had similar durations of remission. No difference was observed
between groups either in the mean total number of treatments needed to clear
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psoriasis or in the length of remission achieved. Group III received a lower dose of
UVA toachieve thesame durationof remission than Groups Iand II (p < 0.0005),
and Group 11 received less than Group I (p < 0.05).
TABLE
Average numberofclearing treatments, mean dose ofUVA andmean duration of
remission in 3 groups ofpatients with psoriasis on PUVA therapy
Average number of treatments Dose of UVA Duration of
Group on clearing regimen joules/cm2 remission
(± SEM) (±SEM) (months ± SEM)
1 21.0 0.8 87.8 ± 4.9 8.53 ± 0.6
11 21.2 0.6 77.0 4.1 9.20 ± 0.5
III 21.6 0.5 51.0 1.7 8.77 + 0.6
Nausea and itching of the skin were the only reported side effects. Mild nausea
was common, but in only five patients was it severe. Eight patients had mild to
moderate itching during PUVA therapy. No other serious side effects were
observed in the patients studied. Nohaematological or biochemical changes were
detected. No ophthalmological changes were found in anyofthe patients studied.
DISCUSSION
We studied three groups of 30 age- and sex-matched patients with chronic
plaque psoriasis who had received PUVA therapy, and found that it is possible to
obtain a reasonable period of remission from psoriasis with or without mainten-
ance PUVA therapy. There are relatively few reports about the lengths of
remission periods after stopping PUVA therapy.5,6,7,8,9 In these reports the
remission period after clearing treatment varied from 5 weeks to 8 months, and
our results are in agreement. The value of maintenance therapy with PUVA was
first questioned in 1977 when PUVA therapy had just been introduced.10 Other
workers7,8 claim that maintenance treatment will prolong the remission periods
and thus reduce the total cumulative UVA dosage received by the patients even if
they have to go back on a clearing regimen at a later date. Our results do not
support this view in that the remission period was similar in all the groups studied
whether or not maintenance PUVA was used. However, Warin in a later study 11
reported that recurrent courses of PUVA therapy may reduce total cumulative
UVA exposure and economic cost. We would agree with this observation and can
keep the cumulative UVA dosage significantly reduced with no maintenance
PUVA, while still achieving a comparable remission period. Owing to the
markedly reduced dose of UVA received by patients who had no maintenance
PUVA, we consider that after the clearing regimen PUVA therapy should be
stopped and clearing courses should only be repeated if required owing to
relapse.
The risks associated with PUVA therapy will almost certainly be due to the
cumulative total UVA exposure. The cumulative effects of continued treatment
are not yet known. Various modifications such as low-dose PUVA,9 frequent rest
periods between treatmentsand combination withotheragents such asretinoids12
may be instituted to reduce the cumulative UVA dose.
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